David E. Darden
AbbVie
10 Papers
142 Citations
David E. Darden is an academic researcher from AbbVie. The author has contributed to research in topics: Venetoclax & Internal medicine. The author has an hindex of 8, co-authored 10 publications.
Chat about Author
Papers
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
Matthew S. Davids,Andrew W. Roberts,Mary Ann Anderson,John M. Pagel,Brad S. Kahl,John F. Gerecitano,David E. Darden,Cathy E. Nolan,Lori A. Gressick,Jianning Yang,Brenda J. Chyla,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,John F. Seymour +16 more
TL;DR: ABT-199 demonstrated antitumor activity against a variety of human cell lines and xenograft models that include B cell NHL, follicular lymphomas (FL), diffuse large B-cell Lymphoma (DLBCL) and MCL and was recommended for a phase-2 dose.
49
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
John F. Seymour,Matthew S. Davids,John M. Pagel,Brad S. Kahl,William G. Wierda,Thomas P. Miller,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,David C.S. Huang,David E. Darden,Lori A. Gressick,Cathy E. Nolan,Jianning Yang,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,Andrew W. Roberts +19 more
TL;DR: This Ph I dose-escalation study included evaluations of safety, pharmacokinetics and preliminary efficacy of ABT-199 in patients with R/R CLL, including patients with del(17p) and F-refractory CLL.
36
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
Philippe Moreau,Asher Chanan-Khan,Andrew W. Roberts,Amit Agarwal,Thierry Facon,Shaji Kumar,Cyrille Touzeau,David E. Darden,Lura Morris,Jeremy A. Ross,Ahmed Salem,Wijith Munasinghe,Ming Zhu,Joel D. Leverson,Paulo Maciag,Sari H. Enschede,Maria Verdugo,Rod A. Humerickhouse,Simon J. Harrison +18 more
TL;DR: This Phase 1 study evaluates venetoclax with BTZ and dexamethasone (Dex) in patients (pts) with relapsed/refractory MM and results suggest the drug is likely to be safe and effective in these patients.
20
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Matthew S. Davids,John F. Seymour,John F. Gerecitano,Brad S. Kahl,John M. Pagel,William G. Wierda,Mary Ann Anderson,David E. Darden,Cathy E. Nolan,Lori A. Gressick,Jianning Yang,Brenda Chyla,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,Andrew W. Roberts +17 more
TL;DR: BCL-2 is highly expressed in NHL, including mantle cell lymphoma (MCL), and is a promising therapeutic target as it is involved in NHL pathogenesis and mediates resistance to many ...
15
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study
John F. Seymour,Matthew S. Davids,Mary Ann Anderson,Thomas J. Kipps,William G. Wierda,John M. Pagel,Brad S. Kahl,Thomas P. Miller,David E. Darden,Cathy E. Nolan,Lori A. Gressick,Hao Xiong,David C.S. Huang,Brenda J. Chyla,Todd A. Busman,Alison M. Graham,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,Andrew W. Roberts +19 more
TL;DR: ABT-199 shows single agent anti-tumor activity in patients with NHL; particularly in MCL and DLBCL; and no dose-limiting toxicities have been identified to date.
12